首页> 外文期刊>Journal of drugs in dermatology: JDD >Adapalene 0.1% Lotion in the Treatment of Acne Vulgaris: Results From Two Placebo-controlled, Multicenter, Randomized Double-blind, Clinical Studies
【24h】

Adapalene 0.1% Lotion in the Treatment of Acne Vulgaris: Results From Two Placebo-controlled, Multicenter, Randomized Double-blind, Clinical Studies

机译:Adapalene 0.1%乳液治疗寻常型痤疮:两个安慰剂对照,多中心,随机双盲临床研究的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Acne vulgaris is a common chronic skin disease affecting roughly 15 percent of the general population and up to 85 percent of adolescents and young adults. Adapalene, a synthetic naphthoic acid derivative with retinoid activity, has demonstrated good clinical efficacy in the treatment of acne if used with full compliance. Objectives: To evaluate the efficacy and assess safety of a new adapalene formulation, adapalene 0.1 % lotion, versus the lotion vehicle in subjects with acne vulgaris. Methods: Subjects were randomized to receive either adapalene 0.1 % lotion or its vehicle once daily for 12 weeks in two multi-center, randomized, vehicle-controlled, double-blind, parallel group studies. Efficacy was evaluated using two co-primary endpoints: Investigator Global Assessment (IGA) of success rate (defined as the proportion of subjects who achieved at least a two point reduction, on a 5-point scale, from baseline to week 12 in IGA score); and the absolute change from baseline to week 12 in total, inflammatory and non-inflammatory lesions. Signs of local skin irritation and routine clinical safety parameters were evaluated throughout both studies. Results: in total, 2,141 subjects were included in the two studies: 1,068 patients received adapalene 0.1 percent lotion and 1073 received the vehicle. In both studies, adapalene 0.1% lotion was shown to be significantly more effective than its vehicle in improvement in the IGA success rate. Adapalene 0.1 % lotion was also significantly superior to its vehicle in all three lesion reduction measures: total, inflammatory and non-inflammatory. Reports of application site skin irritation in the adapalene 0.1 % lotion treatment group were transient and mild or moderate in severity, with only a few being severe. Additionally, according to patient surveys, the lotion formulation was found to be easily spreadable, easily absorbed and pleasant to use. Conclusion: Adapalene 0.1% lotion used once a day for 12 weeks is effective and well tolerated in the treatment of acne vulgaris.
机译:背景:寻常痤疮是一种常见的慢性皮肤病,约占总人口的15%,青少年和年轻人的比例高达85%。阿达帕林是一种具有类维生素A活性的合成萘甲酸衍生物,如果完全合规使用,已显示出治疗痤疮的良好临床疗效。目的:评估新型阿达帕林制剂(阿达帕林0.1%洗剂)相对于寻常痤疮受试者的洗剂媒介物的疗效和安全性。方法:在两个多中心,随机,载体对照,双盲,平行组研究中,受试者随机接受每天一次的0.1%阿达帕林乳液或其媒介物治疗12周。使用两个共同的主要终点对疗效进行评估:成功率的全球研究者评估(IGA)(定义为从基线到IGA评分从第12周到第12周以5分制至少降低两分的受试者比例);以及从炎性到非炎性病变从基线到第12周的绝对变化。在两项研究中均评估了局部皮肤刺激症状和常规临床安全性参数。结果:两项研究总共包括2,141名受试者:1,068例患者接受了0.1%的阿达帕林乳液和1073例接受了媒介物。在两项研究中,显示出0.1%的阿达帕林乳液在改善IGA成功率方面比其媒介物有效得多。 0.1%的Adapalene乳液在所有三种减少病变的措施中也明显优于其媒介物:全部,炎症和非炎症。关于阿达帕林0.1%洗剂治疗组中应用部位皮肤刺激的报道是短暂的,轻度或中度的,只有少数是严重的。另外,根据患者调查,发现洗剂配方易于铺展,易于吸收并且使用舒适。结论:每天使用0.1%的Adapalene乳液12周,对寻常性痤疮有效且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号